UNSPSC 51322302: Chondroitin

This classification denotes a glycosaminoglycan with the molecular formula (C14H21NO14S)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6IC1M3OG5Z. European Medicines Agency schedules chondroitin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13355MIG. The term chondroitin sulfate is a U.S. FDA designation. SMILES: CC(=O)NC1C(C(C(OC1O)CO)O)OC2C(C(C=C(O2)C(=O)O)O)O.

UNSPSC 51322302 Chondroitin is a Commodity code that encompasses individual pharmaceutical active ingredients and finished medications sourced by state and local health systems, fire rescue agencies, and pharmacy benefit programs. Recent solicitations show state and local governments purchasing chondroitin and related pharmaceutical compounds as components of broader medication procurement—either as standalone line items within emergency medical supplies or as part of multi-source generic pharmaceutical contracts serving institutional health facilities and state employee benefit plans. The issuing bodies include city and county purchasing departments (notably the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Work under this code ranges from small emergency-supply acquisitions to large-scale multi-state pharmaceutical supply agreements, with vendors required to meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and specific expiration-date and shelf-life guarantees.

Recent activity concentrates in Texas, Minnesota, and Florida. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications to Tampa Fire Rescue in April 2026, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; while that solicitation named specific emergency medications (Labetalol, Epinephrine, Adenosine, Diltiazem), it illustrates the commodity-level purchasing pattern under this code. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products serving state and local facilities across multiple states, with proposals due March 26, 2026 and contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs, signaling exploratory procurement activity in pharmaceutical supply restructuring. Vendors should expect competitive pricing evaluation, strict compliance documentation, and cooperative purchasing participation as significant factors in contract award.